Dr. Reddy's Announces the Launch of Amoxicillin Tablets, Capsules, and Oral Suspension
HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy's Laboratories (NYS: RDY) announced today that is has launched Amoxicillin Tablets, Capsules, and Oral Suspension, a bioequivalent generic version of Amoxil® (Amoxicillin) Tablets, Capsules, and Oral Suspension in the US Market on September 17, 2012. Amoxicillin Tablets (500 mg and 875 mg), Capsules (250 mg and 500 mg), and Oral Suspension (125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, and 400 mg/5 ml) are approved by the United States Food and Drug Administration (USFDA).
The Amoxil® brand and generic Tablets (875 mg) has U.S. sales of approximately $22.2 Million, Capsules has U.S. sales of approximately $67.2 Million, and Oral Suspension has U.S. sales of approximately $89.5 Million, all for the most recent twelve months ending June 2012 according to IMS Health.*
Dr. Reddy's Amoxicillin Tablets in 500 mg and 875 mg are available in bottle counts of 20 and 100. Amoxicillin Capsules in 250 mg and 500 mg are available in bottle counts of 100 and 500. Amoxicillin Oral Suspension in 200 mg/5 ml and 400 mg/5 ml are available in bottle sizes of 50 ml, 75 ml, and 100 ml. Amoxicillin Oral Suspension in 125 mg/5 ml and 250 mg/5 ml are available in bottle sizes of 80 ml, 100 ml, and 150 ml.
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYS: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: www.drreddys.com
Note to editor: Amoxicillin tablets (500 mg and 875 mg), capsules (250 mg and 500 mg), and oral suspension (125 mg/5 ml, 200 mg/ 5 ml, 250 mg/ 5 ml, and 400 mg/5 ml) are indicated for: Treatment of infection of the ear, nose, throat, genitourinary tract, skin and skin structure, and lower respiratory tract that are due to susceptible strains of designated microorganisms and also in combination for treatment of H. pylori infection and duodenal ulcer disease.
Amoxil® is a registered trademark of GlaxoSmithKline LLC and is licensed to Dr. Reddy's Laboratories, Inc.
*IMS National Sales Perspectives: Retail and Non-Retail MAT June 2012
Dr. Reddy's Laboratories Ltd.
Investors and Financial Analysts:
Kedar Upadhye, +91-40-66834297
Saunak Savla, +91-40-49002135
Milan Kalawadia (USA), +1 908-203-4931
S Rajan, +91-40-49002445
KEYWORDS: United States Asia Pacific North America New York India
The article Dr. Reddy's Announces the Launch of Amoxicillin Tablets, Capsules, and Oral Suspension originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.